Pharmacological prevention of cardiovascular disease in general practice;Medikamentell forebygging av hjerte- og karsykdommer i allmennpraksis

Tidsskrift for den Norske Laegeforening

Volumn 120, Issue 22, 2000, Pages 2643-2647

  Meland, Eivind ^a   Ellekjær, Hanne ^b   Gjelsvik, Bjørn ^b   Kimsås, Alf ^c   Holmen, Jostein ^b   Hetlevik, Irene ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b Samfunnsmedisinsk Forskningssenter ^*  (Norway)

^c Bjerke Legesenter   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METFORMIN; STATIN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; ENZYME INHIBITION; HYPERTENSION; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; RISK ASSESSMENT; TREATMENT PLANNING;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; CASE REPORT; COST-BENEFIT ANALYSIS; DIURETICS, THIAZIDE; ENGLISH ABSTRACT; FAMILY PRACTICE; FEMALE; FIBRINOLYTIC AGENTS; HUMAN; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; META-ANALYSIS; MIDDLE AGE; NORWAY; PRACTICE GUIDELINES; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0034692429     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, red. Evidence based cardiology. London: BMJ Books, 1998.
2. Berglund G. De stora hypertensionsstudierna. Design, resultat och kliniska implikationer. Kungälv: MSD Läkemedel, 1987.
3. Lawrence M, Neil A, Fowler G, Mant D. Prevention of cardiovascular disease. An evidence based approach. Oxford: Oxford University Press, 1996.
4. Hetlevik I. The role of clinical guidelines in cardiovascular risk intervention in general practice. Doktoravhandling. Trondheim: Institutt for samfunnsmedisinske fag, Norges teknisk-naturvitenskapelige universitet, 1999.
5. Meland E. Management of coronary heart disease risk in general practice. General practitioners' assessment of risk, and effects of life style intervention among men with high risk for coronary heart disease. Doktoravhandling. Bergen: Institutt for samfunnsmedisinske fag, Universitetet i Bergen, 1997.
6. Holmen J, Hetlevik I, Ellekjær H, Gjelsvik B, Kimsås A, Meland E. Kliniske retningslinjer for primærhelsetjenesten. Tidsskr Nor Lægeforen 1999; 119: 1794-9.
7. Hetlevik I, Holmen J, Ellekjær H, Gjelsvik B, Kimsås A, Meland E. Kliniske retningslinjer for hypertensjon. Tidsskr Nor Lægeforen 1999; 119: 3037-41.
8. Lindholm L, Hallgren C, Boman K, Markgren K, Weinehall L, Ögren J. Analys av kostnadseffektiviteten vid prevention av hjärt-kärlsjukdom: rankinglista ett hjälpmedel för att rätt fördela resurserna. Läkartidningen 1999; 96: 2858-66.
9. Kristiansen IS. Økonomiske analyser av helsetiltak. Om kostnad-nytte og kostnad-effekt-analyser som hjelpemiddel for bedre ressursbruk. Tidsskr Nor Lægeforen 1990; 110: 2377-81.
10. Jacobsen BK, Schirmer H. Brystkreftrisiko og andre sykdommer - hvor sterkt bar den fremheves? Tidsskr Nor Lægeforen 1999; 119: 3625-7.
11. Petersen H, Næss A-C, Dalsegg A, Lupton B, Olsen JA, Thelle D et al. Behandling av mild hypertensjon. Konsensuskonferanse. Oslo: Norges forskningsråd, Komiteen for medisinsk teknologivurdering, 1997.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
13. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7.
14. Tung C, Mark D. Cost-effectiveness of prevention of cardiovascular disease. I: Yusuf S, Cairns JA, Camm AJ, Fallen EL, Gersh BJ, red. Evidence based cardiology. London: BMJ Books, 1998: 303-14.
15. MRC Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104.
16. Management Committee. The Australian therapeutic trial in mild hypertension. Lancet 1980; 1: 1261-7.
17. Dahløf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension. Lancet 1991; 338: 1281-5.
18. Amery A, Brixko P, Clement D. Mortality and morbidity results from the European working party on high blood pressure in the elderly. Lancet 1985; 2: 1349-54.
19. Hansson L, Zanchetti A, Carruthers SG, Dahløf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
20. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
21. MRC's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-41.
22. Psaty B, Smith N, Siscovick D, Koepsell TD, Weiss NS, Heckbert SR et al. Health outcomes associated with antihypertensive therapies used as first-line agents. JAMA 1997; 277: 739-45.
23. Tuomilehto J, Rastenyte D, Birkenhäger W, Thijs L, Antikainen R, Bulpitt CJ et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-84.
24. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-45.
25. United Kingdom Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
26. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high risk patients. N Engl J Med 2000; 342: 145-53.
27. Rose G, Colwell L. Randomised controlled trial of antismoking advice: final (20 year) results. J Epidemiol Community Health 1992; 46: 75-7.
28. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heait disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
29. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80.
30. Gottlieb S, McCarter R, Vogel R. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-97.
31. Curb J, Pressel S, Cutler J, Savage PJ, Apple-gate WB, Black H et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276: 1886-92.
32. Messerli F, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension n the elderly? JAMA 1998; 279: 1903-7.
33. Meland E, Hafting M, Hetlevik I, Holmen J, Hunskår S. Hjerte og kretsløp. I: Hunskår S, red. Allmennmedisin. Klinisk arbeid. Oslo: ad Notam Gyldendal, 1997: 193-231.
34. Christensen B, Heebøll-Nielsen N, Madsen LD, Lous J, Færgeman O, Stender S et al. Forebyggelse af iskæmisk hjertesygdom i almen praksis - med særligt henblik på dyslipidæmi. Aalborg: Dansk selskab for almen medicin, 1998.
35. Haq I, Ramsay L, Yeo W, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 1999; 81: 40-6.
36. Meland E. Ellekjær H, Gjelsvik B, Kimsås A, Holmen J, Hetlevik I. Forebyggende livsstilsråd mot hjerte- og karsykdommer i primærhelsetjenesten. Tidsskr Nor Lægeforen 2000; 120: 2656-60.
37. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611-6.